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Abstract.
Background: In the care of persons with cognitive problems, it is important to use a valid mild cognitive impairment (MCI)
criterion that discriminates well between normal and pathological aging.
Objective: To find the brief neuropsychological screening criterion that best correlates with cerebrospinal fluid (CSF)
biomarkers for cognitive decline and dementia in persons seeking help for cognitive problems.
Methods: 452 consecutively recruited patients (age 40–80 years) from memory-clinics in the Norwegian national multicentre
longitudinal study Dementia Disease Initiation were included. CSF data as well as full data from brief neuropsychological
screening were available for all patients.
∗Correspondence to: Erik Hessen, Department of Neurology,
Akershus University Hospital, PB 1000, 1478 Lørenskog, Norway.
Tel.: +47 92097373; E-mail: erik.hessen@nevropsykologi.no.
ISSN 1387-2877/19/$35.00 © 2019 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
716 E. Hessen et al. / MCI and CSF Biomarkers
Results: Amnestic MCI, including at least one memory test below T-score 40, outperformed the conventional US National
Institute on Aging-Alzheimer’s Association (NIA-AA) MCI criterion. Only amnestic MCI was significantly associated with
biomarker pattern of NIA-AA stage 2 (low CSF A42 concentrations and elevated tau) in multivariate regression analysis.
Conclusions: The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with
CSF biomarkers for cognitive decline and Alzheimer’s disease is in accordance with longitudinal studies that find memory
impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent
cognitive decline and dementia. The prevalence of pathological biomarkers for Alzheimer’s disease is common in the elderly
and the clinical significance of present findings depend on longitudinal validation.
Keywords: Alzheimer’s disease, amnestic MCI, brief neuropsychological assessment, cerebrospinal fluid biomarkers, mild
cognitive impairment, NIA-AA MCI criterion, NIA-AA stage 2
INTRODUCTION
The prevailing definition of mild cognitive impair-
ment (MCI) due to Alzheimer’s disease (AD) [1]
requires only one impaired neuropsychological test
score, to any cognitive domain (memory, execu-
tive function, attention, language and visuospatial
ability). According to this approach, impairment is
typically defined by scores 1–1.5 standard deviations
(SD) or more below the mean for age- and education-
matched peers on culturally appropriate normative
data.
However, this method has shown vulnerability
to false-positive diagnostic errors [2–4]. With this
approach, Edmonds et al. [4] observed a false-
positive MCI diagnosis in as many as 34.2%
of Alzheimer’s Disease Neuroimaging Initiative
(ADNI) MCI cohort, and false-negative diagnos-
tic errors in 7.1% of ADNI’s cognitively normal
control group. Due to these actuarial diagnostic prob-
lems, Loewenstein et al. [2], Jak et al. [5], and
Bondi et al. [3] used an alternative classification. The
Jak/Bondi criterion requires two or more tests in the
same cognitive domain to be at least ≤1 SD below
the demographically normative mean scores [3, 5].
Longitudinal findings show that, compared to the tra-
ditional criteria, this alternative criterion identifies
more subjects that progress clinically and produces
fewer subjects who return to normal neuropsycho-
logical function at follow-up [3]. One explanation
for the poor diagnostic accuracy of the “one reduced
test” approach is that cognitively healthy individuals
may acquire poor test scores by chance when several
cognitive tests are administered [6]. Of note, studies
of patients with brain impairment of other etiology
than neurodegenerative disease, do also suggest that
the best balance between sensitivity and specificity is
achieved with a mild cut off for impairment of 1 SD
below the normative mean [7, 8].
While comprehensive neuropsychological assess-
ment may be qualitatively better than a brief
assessment with fewer tests [3], a disadvantage is
that comprehensive testing is time consuming, which
makes it less efficient and thus less available. For effi-
ciency, many memory clinics therefore employ brief
cognitive assessments and use the prevailing defi-
nition for MCI [1], despite evidence of diagnostic
superiority of more comprehensive assessment with
alternative impairment criteria [2–4].
In the study of patients presenting with neurode-
generative diseases, the most meaningful outcome is
a valid prediction of longitudinal cognitive change.
In a cross-sectional validation study of cognitive
impairment criteria, a biomarker signature consid-
ered a risk factor for development of AD can be a
surrogate for this goal. The US National Institute
on Aging-Alzheimer’s Association (NIA-AA) sug-
gested in 2011 a “preclinical stage of AD”, defined
as patients without impaired cognition on standard
assessments but positive biomarker evidence for AD
[1]. According to this suggestion, stage 0 implies
both amyloid and tau markers negative; stage 1
being lowered cerebrospinal fluid (CSF) amyloid-
beta (A)42 concentrations but negative tau markers;
stage 2, lowered CSF A42 concentrations and ele-
vated tau concentrations; and stage 3, biomarker
pattern as in stage 2 with ‘subtle cognitive decline’
as evidenced by reduced neuropsychological test per-
formance. In a recent longitudinal study (n = 122)
following memory clinic patients on average 4 years
without objective cognitive impairment, we found
that biomarker-based classifications according to the
NIA-AA ‘preclinical AD’ stage 2 was the best predic-
tor of cognitive decline, dementia, and AD dementia
[9]. A similar finding was reported in a five-year fol-
low up [10] where a progression rate to probable mild
dementia (CDR ≥0.5) was 26% in participants classi-
fied as stage 2 at baseline, and 56% in those classified
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as stage 3. In a smaller 6-year longitudinal study of
81 memory clinic patients that only displayed subjec-
tive cognitive decline (SCD), findings suggested that
pathological CSF A42 (similar to stage 1), predicted
conversion to dementia [11]. This is in line with other
studies [12, 13]. With regard to prognosis of amnestic
versus non-amnestic MCI, our previous longitudinal
studies revealed that MCI with memory impairment,
either as a single domain deficit or in the context of a
multi-domain deficit, is a stronger predictor of cog-
nitive decline and dementia than non-amnestic MCI
[15, 16].
Based on the findings described above, we chose
to validate different cognitive MCI criteria against
the biomarker pattern of NIA-AA stage 2 (lowered
CSF A42 concentrations and elevated CSF tau con-
centrations). We hypothesized that a MCI criterion,
including mild amnestic deficit (Memory score 1
SD or more below normative mean), would show
a stronger association with the biomarker pattern of
NIA-AA stage 2, than both the conventional NIA-
AA MCI criterion and an MCI criterion similar to
the criterion suggested by Jak et al. and Bondi et al.
[3, 5].
METHODS
The study was approved by the regional medi-
cal research ethics committee. All participants gave
their written informed consent before taking part. All
further study conduct was in line with the guide-
lines provided by the Helsinki declaration of 1964;
revised 2013 and the Norwegian Health and Research
Act.
Patients were consecutively recruited from mem-
ory clinics and neurological centers that take part
in the national multicenter longitudinal collabora-
tion Dementia Disease Initiation (DDI), aiming at
detection of early biological and cognitive markers
for dementia. A detailed description of inclusion ad
exclusion criteria is given in Fladby et al. [17]. Sub-
jects in the present part of the study were recruited
between January 2013 to November 2017. In sum-
mary, inclusion criteria were age 40–80 years, recent
appearance of cognitive concerns or symptoms and
a native language of Norwegian, Swedish, or Dan-
ish. Exclusion criteria were brain trauma or disorder,
including clinical stroke, dementia, severe psychi-
atric and/or somatic disease that may account for
symptoms, intellectual disability or other develop-
ment disorder.
The DDI-study employ the NIA/AA [1] and Jessen
et al. [18] criteria for stage classification, and dis-
ease diagnosis. By December 2017, CSF data as
well as full data from brief cognitive screening was
available for 452 patients with cognitive concerns or
symptoms.
Clinical assessment
A Case Report Form (CRF) was completed for all
the patients, including standardized assessments of
medical history from subject and informant, physical
and neurological examinations, including the Mini-
Mental State Examination (MMSE) [19], Geriatric
Depression Scale (GDS), and brief neuropsycho-
logical screening. The brief neuropsychological
assessment includes six cognitive functions. All the
test scores were converted to T-scores based on avail-
able normative data.
1. Delayed verbal recall (Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD)
word list) [20, 21].
2. Delayed verbal recognition (CERAD word list)
[20, 21].
3. Visuoperceptual ability (Visual Object Space
Perception (VOSP) silhouettes) [22].
4. Psychomotor speed (Trail Making A, TMT-A)
[23].
5. Cognitive flexibility/divided attention (Trail
Making B, TMT-B) [23].
6. Phonetic word fluency (Controlled Oral Word
Association Test, COWAT) [24].
We tested the three following neuropsychological
algorithms against the NIA-AA stage 2:
(1) A stringent version of the NIA-AA MCI crite-
rion [1], as employed in the DDI study: at least
one test score in any cognitive domain similar
to or below T-score 35.
(2) A criterion similar to the suggestion of Jak
et al. [5] and Bondi et al. [3]: at least two test
scores in any cognitive domain below T-score
40.
(3) Amnestic MCI: at least one test score below
T-score 40, including at least one memory test.
Additionally, these algorithms were tested inde-
pendently against the criteria for abnormal A42,
total tau (T-tau), and phosphorylated tau (P-tau) [25,
26].
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Biomarkers
CSF samples were obtained by lumbar puncture
using a standardized protocol. Lumbar puncture was
performed before noon, and CSF was collected in
polypropylene tubes (Thermo Nunc) and centrifuged
within 4 h at 2000 g for 10 min at room temperature.
The supernatant was transferred to new tubes and
frozen at –80°C prior to analysis. All CSF samples
were analyzed at the Department of Interdisciplinary
Laboratory Medicine and Medical Biochemistry at
Akershus University Hospital, and samples from
other sites were frozen before sending to this lab-
oratory. We analyzed CSF concentrations of T-tau,
P-tau181, and A42 by using ELISA (Innotest -
Amyloid (1–42), Innotest h-Tau Ag and Innotest
Phospho-Tau (181P), Fujirebio, Ghent Belgium. The
following cut-off values for CSF T-tau and P-tau
abnormality were applied according to the labora-
tory recommendations (modified from Sjögren et al.
2001) [25]; t-tau >300 pg/ml for age <50 years, >450
pg/ml for age 50–69 years, and >500 pg/ml for age
≥70 years and p-tau ≥80 pg/ml. An optimal cut-off at
CSF A1-42 <708 for amyloid plaque pathology was
determined following DDI PET [18F]-Flutemetamol
uptake studies [26]. NIA-AA stage 2 classification
have both pathological A42 and T-tau, showing evi-
dence of amyloidosis and neurodegeneration.
Statistics
Descriptive statistics of the demographic, clini-
cal, behavioral, and cognitive characteristics of the
patient population was analyzed. Group comparisons
were tested using Pearson’s Chi-square for categor-
ical variables and independent samples t-tests for
continuous variables. Odds ratios for occurrence of
NIA-AA stage 2, based on the three neuropsycho-
logical algorithms specified in the introduction as
well as age and years of education was estimated
with logistic regression analysis. Univariate analyses
were first performed for variables reported in Table 3,
and significant factors were included in the multi-
variate analysis. Results of the multivariate analysis
are presented with odds ratios (OR) with 95% con-
fidence intervals (CI) and p-values. All tests were
performed at a 5% significance level. Similar analyses
were performed with the employed criteria for abnor-
mal A42, T-tau, and P-tau as dependent variables.
The Statistical Package for Social Sciences (SPSS)
version 25 was used.
RESULTS
Demographic, clinical, and cognitive scores for the
patient population are provided in Table 1. Table 2
shows scores for patients fulfilling the biomarker
pattern of NIA-AA stage 2 criterion (n = 53) or not
(n = 398). The two groups are significantly different
on most of the variables, but similar with regard to
gender, years of education as well as on three of the
six neuropsychological tests (COWAT, TMT-A, and
VOSP silhouettes).
Univariate logistic regression analysis showed
significant associations with the dependent vari-
able (NIA-AA stage 2) for amnestic MCI (n = 144)
(OR = 5.7, CI 3.1-10.6, p = 0.001), age at inclusion
(OR = 1.1, CI 1.0-1.1, p = 0.001), for the MCI con-
dition requiring two or more tests below T = 40 in
any cognitive domain (n = 152) (OR = 3.9, CI 2.1-
7.0, p = 0.001) and for the condition requiring one
test or more similar to or below T = 35 in any
Table 1
Demographic, clinical, and cognitive scores for the patient population
Variables All patients (n = 452)
Mean age (range) (SD) 63.2 (40–84) (9.3)
Female (%) 49.3
Education, y (range) (SD) 13.7 (7–22) (3.3)
MMSE (range) (SD) 28.5 (20–30) (1.8)
A42, ng/l (range) (SD) 955.28 (300–1880) (291.0)
T-tau, ng/l (range) (SD) 376.71 (75–1370) (226.8)
P-tau, ng/l (range) (SD) 59.66 (16–185) (28.1)
CERAD, recall, T-score (range) (SD) 46.8 (14–69) (14.4)
CERAD, recognition, T-score (range) (SD) 46.7 (10.0–57.6) (14.7)
COWAT, T-score (range) (SD) 48.4 (24–77) (9.9)
TMT-A, T-score (range) (SD) 45.2 (12–74) (10.5)
TMT-B, T-score (range) (SD) 46.1 (9–76) (11.3)
VOSP silhouettes, T-score (range) (SD) 48.5 (15–70) (11.2)
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Table 2
Demographic, clinical, and cognitive scores for patients fulfilling NIA-AA stage 2 criterion or not
Variables Fulfilling NIA-AA stage 2 Not fulfilling NIA-AA stage 2 p
(n = 53) (n = 398)
Mean age (range) (SD) 67.8 (50–81) (7.8) 62.6 (40–84) (9.3) 0.001
Male/female (n) 197/200 31/22 0.45
Education, y (range) (SD) 13.9(7–20) (3.4) 13.7 (7–22) (3.3) 0.78
MMSE (range) (SD) 26.9(21–30) (2.3) 28.7 (20–30) (1.6) 0.001
A42, ng/l (range) (SD) 557.3(300–700) (95.1) 1008.3 (300–1880) (266.1) 0.001
T-tau, ng/l (range) (SD) 783.0(443–1370) (237.4) 322.6 (75–1170) (160.4) 0.001
P-tau, ng/l (range) (SD) 108.1(63–185) (31.4) 53.2 (16–185) (20.4) 0.001
CERAD, recall, T-score (range) (SD) 34.5 (14–69) (15.2) 48.5 (14–69) (13.5) 0.001
CERAD, recognition, T-score (range) (SD) 26.5 (10.0–58) (17.6) 48.3 (10–58) (13.6) 0.001
COWAT, T-score (range) (SD) 49.0 (26–69) (9.5) 48.3 (24–77) (10.0) 0.62
TMT-A, T-score (range) (SD) 43.6 (12–66) (10.4) 45.4 (14–74) (10.5) 0.24
TMT-B, T-score (range) (SD) 41.7 (9–70) (14.4) 46.6 (11–76) (10.8) 0.02
VOSP silhouettes, T-score (range) (SD) 46.2 (22–70) (11.0) 48.8(15–70) (11.3) 0.12
Table 3
Univariate and multivariate regression analysis [dependent variable: NIA-AA stage 2 = lowered
cerebrospinal fluid (CSF) A42 concentrations, and neurodegeneration (elevated CSF
tau concentrations)]
Variable Univariate p Multivariate p
Analysis Analysis
OR (95% CI) OR (95 % CI)
One test or more < T = 40, including at least
one memory test
5.7 (3.1–10.6) 0.001 4.4 (1.9–10.4) 0.001
Age at inclusion 1.1 (1.0–1.1) 0.001 1.1 (1.0–1.1) 0.007
Two or more tests < T = 40 in any cognitive
domain
3.9 (2.1–7.0) 0.001 2.2 (0.9–5.5) 0.093
One test or more < T = 35 in any cognitive
domain (NIA-AA MCI criterion)
2.9 (1.6–5.4) 0.001 0.5 (0.2–1.5) 0.243
Years of education 1.0 (0.9–1.1) 0.77
cognitive domain (NIA-AA MCI criterion) (n = 204)
(OR = 2.9, CI 1.6-5.4, p = 0.001) (Table 3). Only
the amnestic variant of MCI (OR = 4.4, CI 1.9-10.4,
p = 0.001) and age at inclusion (OR = 1.1, CI 1.0-1.1,
p = 0.007) remained significant in the multivariate
analysis. Similar results were revealed both in uni-
variate and in multivariate analysis with abnormal
levels of T-tau, P-tau, and A42 as dependent vari-
ables. In multivariate analysis the association was
significant for all the variables with the amnestic vari-
ant of MCI, T-tau (OR = 3.1, CI 1.7-5.9, p = 0.001),
P-tau (OR = 2.1, CI 1.1-4.1, p = 0.023), and A42
(OR = 2.2, CI 1.2-4.0, p = 0.01). Similar findings were
evident for age at inclusion, T-tau (OR = 1.0, CI 1.0-
1.1, p = 0.014), P-tau (OR = 1.1, CI 1.0-1.1, p = 0.001)
as well as A42 (OR = 1.1, CI 1.0-1.1, p = 0.001).
Additionally, abnormal level of A42 was in mul-
tivariate analysis significantly associated with the
MCI condition requiring two or more tests below
T = 40 in any cognitive domain (OR = 2.3, CI 1.2-4.4,
p = 0.017).
DISCUSSION
The main finding of this study is that amnes-
tic MCI, including at least one memory test below
T-score 40, outperformed both the conventional NIA-
AA MCI criterion and the MCI condition similar to
the criterion suggested by Bondi et al. and Edmonds
et al. [3, 4]. Amnestic MCI was the only MCI criterion
that was significantly associated with the biomarker
pattern of NIA-AA stage 2 in multivariate regression
analysis. While the odds ratio for occurrence of NIA-
AA stage 2 was high (OR: 4.4) for patients classified
according to amnestic MCI, it was associated with
a low probability of NIA-AA stage 2 (OR: 0.5) for
patients classified according to the conventional NIA-
AA MCI criterion. Age at inclusion was also slightly
associated (OR: 1.1) with the biomarker pattern of
NIA-AA stage 2.
Similar results were also evident when the same
independent variables (age, years of education and
abnormal levels of CSF T-tau, P-tau, and A42) were
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tested independently in multivariate analysis against
the employed MCI criteria. Of particular interest is
that the conventional MCI criterion was not asso-
ciated with any of the independent variables in the
multivariate analysis.
The NIA-AA stage 2 has been found to increase
the risk of subsequent cognitive decline in patients
with no or only subjective cognitive decline at base-
line [9, 10]. The rather mild amnestic impairment
criterion used in this study showed a stronger asso-
ciation with the biomarker-pattern characteristic of
this stage, than the most commonly used NIA-AA
MCI criterion [1] and a variant of the Jak/Bondi
criterion [5, 3]. This suggests that the amnestic
MCI criterion as applied here is precise and pos-
sibly predictive of later cognitive decline in cases
where a brief neuropsychological protocol is avail-
able. The association of the amnestic MCI criterion
with lowered CSF A42 concentrations and elevated
CSF tau concentrations (as in NIA-AA stage 2),
suggests that those who display mild memory impair-
ment are most likely to also display hallmark AD
biomarker pathology, according to the NIA-AA sug-
gestion from 2011. However, it is necessary to bear
in mind that the amyloid cascade hypothesis, imply-
ing lowered CSF A42 concentrations as the initial
sequence of events in AD, recently has been chal-
lenged. Studies have found low correlations between
AD biomarkers across disease stages [27], a con-
siderable proportion of subjects with MCI develop
AD in the absence of pathological amyloid [10, 28],
and many elderly have lower CSF A levels but nor-
mal cognitive function [29]. A recent Swedish study
found that 46% of cognitively well-functioning 70-
year-olds had at least one pathological AD biomarker
[30]. While associations between MCI classifica-
tions and biomarkers are informative, the true test
and validation of MCI criteria requires longitudi-
nal follow up. With slightly different test batteries,
our previous longitudinal studies showed that MCI
with memory impairment, either as a single domain
deficit or in the context of a multi-domain deficit, is
a stronger predictor of subsequent cognitive decline
and dementia than non-amnestic MCI [15, 16]. This
indicates that the present findings may have some
interest beyond the association with pathological
CSF biomarkers at baseline. In a two-year follow up
study, Hessen et al. [15] found that 29% percent of
patients with pure amnestic MCI and 59% percent
of patients with amnestic, multi domain MCI con-
verted to dementia as opposed to only 10% of patients
with non-amnestic MCI. In the present study, both
the NIA-AA MCI criterion [1] and a variant of the
criterion suggested by Jak et al. and Bondi et al. [3,
5] do not require memory problems and thus, may
contain many subjects with possibly more benign
non-amnestic MCI.
The relatively poor association, in a multivariate
context, between the condition similar to the cri-
terion suggested by Jak et al. and Bondi et al. [3,
5] (in this study, at least two tests in any cognitive
domain below T-score 40) and the biomarker pat-
tern of NIA-AA stage 2, may be explained by the
different preconditions in this study and the original
works by Jak et al. [5] and Bondi et al. [3]. They
employed somewhat more comprehensive neuropsy-
chological assessment than the brief assessment in
this work. Furthermore, their seemingly lenient MCI
criterion (only 1 SD below expected mean) is possi-
bly not so lenient, as this criterion differ from other
criteria with the requirement of 2 mildly impaired
neuropsychological tests scores (–1 SD) in the same
cognitive domain. Based on this they achieved a
robust MCI score with a higher percentage of sta-
ble MCI subjects (i.e., did not revert back to normal
test scores at follow up) and a higher percentage of
subjects that converted to dementia at follow-up, than
patients classified according to more typical MCI cri-
teria [1]. This kind of criterion has also shown distinct
cortical atrophy characteristics, not captured by the
traditional criteria [31].
Previous reports seem to suggest that a compre-
hensive neuropsychological assessment is superior
to brief cognitive assessments. However, this is
not universally supported. One study found that
single neuropsychological tests can be superior to
biomarkers as predictors of cognitive decline, in par-
ticular tests of learning and memory [32]. Another
study that explored the best combination of mul-
tiple AD biomarkers and neuropsychological tests
in predicting subsequent decline, found that CSF t-
tau/amyloid and MRI biomarkers, together with the
combination of only two neuropsychological tests
of memory and executive function were the best
predictors [33]. Among several single-predictor mod-
els (biomarkers and neuropsychological test scores),
both entorhinal cortex volume and TMT-B had sim-
ilar predictive utility as multimarker predictors at
determining those that would deteriorate clinically
over 3 years [33]. Similar utility of neuropsycho-
logical testing as compared with neurobiological
metrics have been reported in several other studies
[34–36]. Taken together, these findings suggests that
the prediction of subsequent decline in the context
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of MCI do not necessarily require a comprehensive
neuropsychological evaluation, supporting further
exploration of the utility of brief assessments in this
endeavor.
The present study has some limitations. Our moti-
vation for utilizing NIA-AA ‘preclinical AD’ stage
2 [1] is that this biological profile was the best
predictor of cognitive decline, dementia, and AD
dementia in our 4–6 year follow up of SCD patients
[9]. NIA-AA recently published an updated research
framework based on a biological definition of AD
to replace the guidelines from 2011 [37]. Imaging
and/or biofluid biomarkers for A deposition (A),
neurofibrillary pathology (T), and neurodegeneration
(N) are categorized as separate biomarker signatures
[AT (N)], the first two (A,T) as AD-specific whereas
the third (N) signifies neurodegeneration that also
may be seen in other diseases. Thus, a possible prob-
lem with the NIA-AA ‘preclinical AD’ stage 2 is
the inclusion of markers both specific for AD (low-
ered CSF A42 and elevated CSF P-tau) as well
markers that also is associated with other etiologies
than AD (elevated CSF T-tau) [37]. As the novel
research framework allows for better differentiation
between AD specific markers and markers associated
with suspected non-Alzheimer pathologic change,
this framework has a probable advantage over the
older classification, and should be validated against
cognitive signatures and criteria for cognitive impair-
ment, and tested in future longitudinal studies of
persons at risk for cognitive decline and dementia.
Another limitation of the study is the cross-sectional
design that precludes interpretation of how cogni-
tive functioning develops during the course of the
disorder.
In conclusion, we found that amnestic MCI based
on brief neuropsychological testing and a MCI
criterion customized to this test battery is signifi-
cantly associated with CSF biomarkers for cognitive
decline. In contrast, when we used the prevailing
NIA-AA MCI criterion, non-significant associa-
tions were found. However, since the prevalence
of pathological biomarkers for cognitive decline
and AD is very common, the clinical significance
of the present findings depends on longitudinal
validation.
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